The Centers for Medicare & Medicaid Services yesterday announced Medicare coverage for monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency. CMS said the coverage will apply to bamlanivimab, the Lilly therapeutic that earned an emergency use authorization earlier this week. Additionally, the agency said it anticipates that bamlanivimab and other, similar therapies will initially be given by drug makers to health care providers at no charge; as such, the Medicare program will not pay for monoclonal antibody products that providers receive for free.

Medicare will, however, reimburse for these therapies’ infusion. Once health care providers begin purchasing monoclonal antibody products, CMS anticipates setting the payment rate in the same manner it uses to set COVID-19 vaccine payments. Additional details for providers about Medicare coding, payment and billing for monoclonal COVID-19 products and their administration are described in CMS’ Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…